In vitro Characterization of Recombinant Human BuChE (Protexia) as a Potential Bioscavenger
Abstract
OBJECTIVES: (1) Demonstrate improved medical protection against nerve agents; (2) Develop a prophylactic that detoxifies nerve agents at a rate sufficient to protect against 5LD-50 exposure; (3) Prophylactic should: Be non-toxic - Product no adverse side effects - Have no adverse effect on performance - Be easy to administer - Have a long biological half-life. CONCEPT: Provide a pretreatment capable of protecting against up to 5xLD-50 of nerve agent with no side effects and no need for additional protective clothing or therapy.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2005
- Accession Number
- ADA449783
Entities
People
- Akrati Saxena
- B. P. Doctor
- C. N. Karatzas
- D. M. Cerasoli
- David E. Lenz
- E. M. Griffiths
- H. Wilgus
- N. H. Greig
- Q. S. Yu
- Yihe Huang
Organizations
- United States Army Medical Research Institute of Chemical Defense